ARCHIVES

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

This article is from The Cancer Letter archive.

Vol. 35 No. 8 | August 31, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: Best Guess On NCI Director: Brown First Choice, Benacerraf Second; FDa On Saccharin

April 22, 1977

New NCI Grant Program Will Support Young Scientists In Innovative, “Risky” Research

May 27, 1977

In Congress: House Subcommittee Postpones FY2000 Markup; Porter Seeks 8% increase for NIH

July 23, 1999

Cancer Planners Revise Some Project Areas, Drop Some, Add New Ones

February 8, 1974

Cech To Step Down At HHMI In 2009.

April 18, 2008

Guidelines Adopted For Pathology Review

February 22, 1980